Cathiva

Gene therapy is emerging as a promising treatment for many cardiovascular diseases; however, companies developing these gene therapies face a significant challenge: the lack of an effective delivery method into the myocardium. Cathiva is revolutionizing therapeutic delivery by developing an innovative catheter device designed to deliver therapeutics into the heart through multiple needles, ensuring targeted delivery across any heart chamber. Our device will improve patient outcomes by providing a simple and efficient method that directly delivers therapeutics into the myocardium, removing the risk associated with systemic delivery, reducing procedure time and cost, and covering more surface area to better treat genetic cardiovascular diseases.

• Employees 3